Global clinical trials activity decreased by 15.3% in Q3 2022, when compared with the same quarter in 2021, according to GlobalData.
Industry sponsored trials accounted for a 51.8% share of overall activity in Q3 2022, an increase of 3.7% when compared with Q3 2021.
Non-industry sponsored trials accounted for a 48.2% share of all clinical trials in Q3 2022, marking a decrease of 3.7% when compared with the same period in 2021.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Q3 2022 industry sponsored clinical trials activity by therapy areas
Oncology was the leading therapy area for industry sponsored clinical trials in Q3 2022, accounting for a 28.9% share of all trials.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThis was followed by Central Nervous System with a 13.9% share, Infectious Disease with 13.6%, Metabolic Disorders with 8.5% and Gastrointestinal with 6.7%.
In Q3 2021, Oncology led with a 26.4% share, followed by Infectious Disease with 16.5%, Central Nervous System with 15.3%, Cardiovascular with 8.3%, and Metabolic Disorders with 8.3%.
| Industry sponsored trials: Q3 2022 vs Q3 2021 | |||
|---|---|---|---|
| Therapy Area | Q3 2021 | Q3 2022 | Activity |
| Oncology | 26.4% | 28.9% |  |
| Central Nervous System | 15.3% | 13.9% |  |
| Infectious Disease | 16.5% | 13.6% | |
| Metabolic Disorders | 8.3% | 8.5% | |
| Gastrointestinal | 7.5% | 6.7% | |
| Cardiovascular | 8.3% | 6.6% | |
| Dermatology | 4.8% | 5.5% | |
| Respiratory | 5.9% | 4.9% | |
| Immunology | 5.2% | 4.4% | |
| Musculoskeletal Disorders | 4.4% | 3.8% | |
| Hematological Disorders | 2.7% | 3.1% | |
| Ophthalmology | 2.9% | 3.0% | |
| Women’s Health | 2.1% | 2.4% | |
| Genito Urinary System And Sex Hormones | 3.1% | 2.3% | |
| Genetic Disorders | 1.5% | 1.9% | |
| Ear Nose Throat Disorders | 1.6% | 1.2% | |
| Male Health | 1.3% | 0.6% | |
| Mouth and Dental Disorders | 0.6% | 0.6% | |
| Hormonal Disorders | 0.8% | 0.5% | |
| Non Malignant Disorders | 0.4% | 0.4% | |
| Nutritional Disorders | 0.3% | 0.2% | |
Most active therapy areas in non-industry sponsored clinical trials
In Q3 2022 the leading therapy area for non-industry sponsored clinical trials was Central Nervous System, accounting for a 26.2% share of all trials.
This was followed Oncology with a 25.8% share, Cardiovascular with 9.7%, Infectious Disease with 9.5%, and Gastrointestinal with 6.5%.
In Q3 2021, Central Nervous System held the lead in non-industry sponsored clinical trials with a 24.3% share, followed by Oncology with 23.2%, Infectious Disease with 13.7%, Cardiovascular with 8.7%, and Gastrointestinal with 6.8%.
| Non-Industry sponsored trials: Q3 2022 vs Q3 2021 | |||
|---|---|---|---|
| Therapy Area | Q3 2021 | Q3 2022 | Activity |
| Central Nervous System | 24.3% | 26.2% | |
| Oncology | 23.2% | 25.8% | |
| Cardiovascular | 8.7% | 9.7% | |
| Infectious Disease | 13.7% | 9.5% | |
| Gastrointestinal | 6.8% | 6.5% | |
| Metabolic Disorders | 5.4% | 6.5% | |
| Musculoskeletal Disorders | 5.7% | 5.4% | |
| Dermatology | 3.0% | 3.7% | |
| Respiratory | 3.7% | 3.7% | |
| Women’s Health | 4.4% | 3.6% | |
| Genito Urinary System And Sex Hormones | 3.1% | 3.4% | |
| Hematological Disorders | 3.1% | 2.9% | |
| Immunology | 3.0% | 2.9% | |
| Mouth and Dental Disorders | 3.0% | 2.9% | |
| Ophthalmology | 2.0% | 2.2% | |
| Genetic Disorders | 0.6% | 1.3% | |
| Ear Nose Throat Disorders | 1.2% | 0.8% | |
| Nutritional Disorders | 0.8% | 0.8% | |
| Hormonal Disorders | 0.9% | 0.7% | |
| Male Health | 0.7% | 0.6% | |
| Non Malignant Disorders | 0.1% | 0.4% | |
Asia-Pacific region has the most activity for industry sponsored clinical trials
Asia-Pacific was the most active region for industry sponsored clinical trials activity in Q3 2022 with a 54.3% share, compared with 58.3% in Q3 2021.
North America was the second most active region with a 32.3% share in Q3 2022, up from 27.8% in Q3 2021, followed by Europe with a 25.6% share in Q3 2022, down from 27.5% in Q3 2021.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Single country studies held an 85.6% share in industry sponsored clinical trials in Q3 2022, compared with 84.5% in Q3 2021. Multinational trials accounted for 14.4% in Q3 2022, against 15.5% in Q3 2021.
Regional activity for non-industry sponsored clinical trials
Asia-Pacific saw the most non-industry sponsored clinical trial activity in Q3 2022 with a 58.9% share, up from 55.6% in Q3 2021.
North America held the second position with a 22.5% share in Q3 2022, compared with 15.3% in Q3 2021. This was followed by Europe with a 13.3% share in Q3 2022, as against 11.3% in Q3 2021.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Single country studies accounted for 98.8% share of non-industry sponsored clinical trials in Q3 2022, compared with 99.2% in Q3 2021. Multinational trials accounted for a 1.2% share in Q3 2022, up from 0.8% in Q3 2021.
Clinical trials by phase in Q3 2022
Phase I trials outnumbered all other studies with a 36.2% share for industry sponsored trials in Q3 2022, compared with 40.6% in Q3 2021.
The share of Phase II trials stood at 35.8% in Q3 2022, up from 32.6% in Q3 2021. Phase III trials increased to 17.1% in Q3 2022, compared with 15.4% in Q3 2021, followed by Phase IV trials with an 11.0% share in Q3 2022, against 11.3% in Q3 2021.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
For non-industry sponsored clinical trials, Phase II activity increased to a 50.7% share in Q3 2022, compared with 40.7% in Q3 2021.
Phase IV trials were the second most active with a 20.6% share in Q3 2022, compared with 23.3% in Q3 2021. Phase I trials held a 17.7% share in Q3 2022, against 16.8% in Q3 2021, followed by Phase III trials with an 11.1% share in Q3 2022, over 19.2% in Q3 2021.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
